Aims/hypothesis TNF-related apoptosis-inducing ligand (TRAIL) is implicated in the regulation of diabetes and is reduced in patients with cardiovascular disease. Although TRAIL receptors are widespread, and TRAIL can promote cell proliferation and apoptosis, it is not known how TRAIL might protect against diabetes and atherosclerosis. Methods We examined the development of atherosclerosis and diabetes in Apoe −/−
Introduction TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, induces apoptosis and proliferation of some cell types [1] [2] [3] . In humans, TRAIL induces apoptosis following engagement with death receptor-4 and -5. Decoy receptor-1 and -2, and osteoprotegerin, which regulates osteoclastogenesis by binding the receptor activator of nuclear factor κB ligand, can compete with the death receptors and protect cells from apoptosis. TRAIL can also promote activation of extracellular signal-regulated kinase 1/2, mitogen-activated protein kinase, c-Jun Nterminal kinase and Akt, pathways that are involved in survival and proliferation of cells [2, 4] .
TRAIL deficiency has been associated with autoimmune diabetes in a mouse model of human type 1 diabetes. For example, the antagonisation of TRAIL signalling by injection of the soluble TRAIL receptor into non-obese diabetic mice or streptozotocin-treated Trail −/− mice increased the incidence of diabetes compared with controls [5, 6] . In cardiovascular disease (CVD), Trail −/− mice were protected from intimal thickening following vascular arterial injury [1] ; moreover, in diabetic Apoe −/− mice TRAIL stabilised atherosclerotic plaque by increasing vascular smooth muscle cell (VSMC) content, and promoted apoptosis of inflammatory cells [7] . Indeed, circulating TRAIL levels tend to be lower in patients with diabetes, and significantly reduced in patients with CVD [8, 9] . Thus, TRAIL may be an important protective factor in diabetes and atherosclerosis. However, mechanisms of its regulatory role remain unexplored. Apolipoprotein E (ApoE)-deficient (Apoe −/− ) mice are unable to produce the key glycoprotein ApoE essential for transport and metabolism of lipids. Compared with normal mice, Apoe −/− mice have markedly altered lipoprotein profiles and rapidly develop atherosclerosis [10] . In this study, we examined the role of TRAIL in diabetes and atherosclerosis by generating Trail −/− Apoe −/− mice. On a 'Western' high-fat diet for 12 weeks, Trail −/− Apoe −/− mice displayed features of diabetes, including increased body weight and adiposity, increased plasma glucose, reduced plasma insulin, increased islet inflammation and apoptosis, impaired glucose tolerance, and ketogenesis. These mice had increased cholesterol and triacylglycerol, in part due to the increased expression of genes regulating cholesterol metabolism and lipogenesis. Trail −/− Apoe −/− mice also exhibited severe atherosclerosis. Thus, the regulation of cholesterol and lipogenesis by TRAIL may reduce the severity of diabetic complications and development of atherosclerosis.
Methods

Animals Trail
−/− mice [11] , backcrossed ten times on to C57BL/6 mice [12] , were obtained from M. Smyth (Peter MacCallum Cancer Centre, Melbourne, VIC, Australia). Trail −/− mice were re-derived and crossed with Apoe −/− mice (JAX Labs, Bar Harbor, ME, USA) on a C57Bl/6 background. Genotyping for Trail and Apoe was performed as previously described [11] or using JAX Labs protocols for ApoE deficiency. Male mice aged 6 weeks and weighing approximately 18 to 20 g were placed on a high-fat 'Western' diet (Semi-Pure Rodent Diet SF00-219; 22% fat, 0.15% cholesterol; Specialty Feeds, Glen Forrest, WA, Australia) for 12 weeks. Mice were killed by cardiac exsanguination. The aortic root was cannulated and flushed with PBS (pH 7.4), followed by perfusion-fixation with 10% formalin (wt./vol). The aortic tree was removed and immersed in fresh fixative. To evaluate aortic lesions en face, fixed descending aortas were opened longitudinally, pinned out and stained with Oil Red O. Prior to killing, mice were monitored daily and body weights recorded weekly. Food intake was monitored over 4 weeks by placing pre-weighed food of known content into clean cages, under the same conditions. The unconsumed feed was carefully collected, weighed once a week and subtracted from the amount given. Daily intake was calculated across the number of animals housed per cage (two to five), where equal intake of food was assumed. All animal work was conducted according to Animal Care and Ethics Committee guidelines, UNSW (Sydney, NSW, Australia).
Plasma and liver analysis Blood was taken via the tail vein or by cardiac puncture at time of killing. Plasma samples were stored at −80°C in EDTA-Na 2 until required for analysis. Triacylglycerol and total cholesterol from plasma (and liver after lipid extraction according to Bligh and Dyer [13] ) were measured using commercial kits (Wako Chemicals, Osaka, Japan). Fasting blood glucose and insulin were measured using kits and as described by the manufacturers (Cayman Chemicals, Ann Arbor, MI, USA, and SPI-bio, Ann Arbor, MI, USA, respectively). Lipoprotein analysis on pooled plasma samples was done by fast protein liquid chromatography as previously described [14] , using a Superose 6HR 10/30 column (GE Healthcare, Uppsala, Sweden), with 500 μl fractions collected and subjected to cholesterol analysis. The HOMA of beta cell function The HOMA of beta cell function (HOMA-B) was used to assess beta cell function. Fasting glucose and insulin were measured at 12 weeks using the HOMA-B equation previously described [15] .
Insulin and glucose tolerance tests At 10 weeks of high-fat feeding, either 1 g/kg body weight D-glucose (Sigma-Aldrich, Sydney, NSW, Australia) or 1 U/kg body weight human insulin was injected into mice intraperitoneally following overnight fasting. Blood was collected by pin prick from a tail vein and plasma glucose was measured using a glucometer (Accu-check Performa; Roche, Mannheim, Germany).
RNA extraction and real-time quantitative PCR Liver and intestine were snap-frozen in liquid nitrogen and stored at −80°C. Tissue was homogenised (MP Biomedicals, Sydney, NSW, Australia) and total RNA extracted in TRI reagent (Sigma) [1] . RNA was then reverse-transcribed to cDNA using iSCRIPT (Bio-Rad, Sydney, NSW, Australia). Realtime PCR was performed in quadruplicate using Sybr Green Master Mix (Applied Biosystems, Mulgrave, VIC, Australia) in the real-time Corbett 6000 thermocycler (Corbett Life Science, Sydney, NSW, Australia). Relative changes in mRNA levels between groups were determined using the 2 ÀΔΔC t method [16] . Expression was normalised to β-actin and changes were compared with Trail Morphometric analysis Morphometric analysis of plaque area:total artery area, media area:total artery area, fibrous cap thickness:plaque area (defined as the VSMC-rich area overlying the necrotic core), necrotic core area:plaque area was performed on elastin-, SMA-, Masson's Trichrome-, and haematoxylin and eosin-stained sections using ImageJ (a public domain Java image processing program inspired by NIH Image) and at least one to two sister sections per artery per mouse. The percentage of positive staining in the plaque or islets was determined using ImageProPlus (Cybernetics, Bethesda, MD, USA). Thresholds for positive staining for each antibody were determined and sections analysed by an investigator blinded to mouse genotype. NIH ImageJ was used to measure area of adipocytes, with at least 100 adipocytes per mouse measured.
Statistics All results are expressed as the mean±SEM. Statistical comparisons were made by Mann-Whitney U tests and one-or two-way ANOVA, with Bonferroni's correction where appropriate. The statistics program in GraphPad Prism Version 4.0 was used (GraphPad Software, San Diego, CA, USA). A value of p<0.05 was considered significant. Increased circulating IL-6 and MCP-1 are associated with type 2 diabetes [18] [19] [20] . A pro-inflammatory cytokine, IL-6 is produced by macrophages in response to infection or tissue insult [21] . Trail −/− Apoe −/− and Trail −/− mice had significantly elevated plasma IL-6 values, which were highest in Trail −/− animals, possibly reflecting the high levels of CD11b-positive leucocytes (Table 1) . MCP-1 is a chemokine that recruits monocytes to areas of injury and is important in atherogenesis [22] . Although no significant differences in plasma MCP-1 were observed between Trail −/− and Apoe −/− mice, plasma from Trail −/− Apoe −/− contained significantly higher levels than plasma from Trail −/− mice (p<0.05) ( Table 1 ). In contrast, plasma IL-1β levels were similar in all strains (Table 1) . (Fig. 3a, b) . To determine the mechanisms underlying this hypercholesterolaemia and hypertriacylglycerolaemia, we examined the expression of genes involved in cholesterol metabolism. 3-Hydroxy-3-methyl-glutarylCoA reductase (HMGCoAR), the rate-limiting enzyme in the cholesterol metabolic pathway, is rapidly induced in mice by high-fat feeding [24] . Hmgcoar mRNA expression was significantly elevated in Trail (Fig. 3c) . Apoe −/− (squares) mice at week 0 and week 12 (n=3-5 per genotype). d Assessment of HOMA-B as described in Methods; n=7-11 per genotype. e Plasma ketone bodies detected using a β-hydroxybutyrate assay; n=4-5 per genotype. f Mouse pancreatic islets stained for insulin, (g) macrophages (MAC3) and (h) apoptosis (active caspase-3); n=5-7 per genotype. Results are expressed as mean±SEM; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001, ANOVA used in all conditions. w, weeks Neimann-Pick C1-like 1 is a sterol transporter of cholesterol for intestinal absorption [25] . Expression of Npc1l1 was also significantly elevated in Trail (Fig. 3d) , whereas Abcg5 mRNA, a gene important for cholesterol transport, was similar in all strains (Fig. 3e) . Thus, increased cholesterol synthesis and absorption are likely to contribute to the elevated cholesterol levels seen in Trail
Results
Trail
To determine whether increased lipogenesis may play a role in the elevated production of triacylglycerol in the liver, and in the increases of plasma VLDL-and LDLcholesterol observed in Trail −/− Apoe −/− mice, we analysed mRNA levels of key lipogenic genes. Expression of Srebp1, Glut2 and Ldlr was significantly higher for all three genes in livers from Trail −/− Apoe −/− compared with (Fig. 3f-h ). Thus, in an Apoe
background, TRAIL-deficiency promotes elevated expression of genes that regulate cholesterol synthesis and absorption, and triacylglycerol production. (Fig. 4a ). Their brachiocephalic arteries had significantly greater plaque area and medial expansion than those of Apoe −/− mice ( Fig. 4b-d) , and aortic root atherosclerosis was also increased (Fig. 4e, f) . In marked contrast, arteries from Trail −/− mice appeared healthy with no signs of atherosclerosis (Fig. 4b) . Interestingly, brachiocephalic plaques from Trail −/− Apoe −/− had significantly less SMA staining, indicating reduced VSMC content ( Fig. 5a ; Table 2 ). Collagen content (Masson's Trichrome) ( Fig. 5b ; Table 2 ) and cap thickness were also significantly reduced in Trail −/− Apoe −/− compared with Apoe −/− plaques ( Table 2) . Trail −/− Apoe −/− plaques had more extensive necrotic cores and macrophage infiltration, with almost double the infiltration in Apoe −/− samples ( Fig. 5c ; Table 2 ). Although PCNA (cell proliferation) levels were not changed ( Fig. 5d ; Table 2 ), significantly increased caspase-3 immunoreactivity was observed in Trail −/− Apoe −/− compared with Apoe −/− plaques, particularly in the shoulder regions ( Fig. 5e ; Table 2 ).
Discussion
In humans with CVD, soluble TRAIL levels are reduced [9] and this has been linked with increased risk of cardiovascular events, independently of conventional risk markers [26] . Reduced circulating TRAIL in older patients with CVD is also associated with increased risk of death over a 6 year period [27] . Furthermore, patients with myocardial infarction display reduced TRAIL levels compared with healthy controls [26] , implicating a protective role for TRAIL in these clinical conditions. TRAIL is a cell surface and soluble ligand that activates TRAIL receptors, of which there are five in humans [2] . TRAIL plays an important role in homeostasis of the immune system, as well as in infection, autoimmune and cancer diseases; it also has apoptotic, Apoe −/− mice develop diabetes when fed a highfat 'Western' diet, also displaying features typical of human disease. This is particularly important since a 'Western' lifestyle with increased consumption of high-energy food has resulted in a pandemic of diabetes and CVD. Second, we show that TRAIL regulates cholesterol and triacylglycerol homeostasis, such that when TRAIL is not present, levels of lipoproteins in Apoe −/− mice are exacerbated. In this system, TRAIL-deficiency worsened the severity of atherosclerosis, a major diabetic complication; these conditions are probably intensified by the chronic inflammation observed in Trail −/− Apoe −/− mice.
Type 2 diabetic patients have increased levels of LDLcholesterol and triacylglycerol, and lower HDL-cholesterol than non-diabetic patients [29] , and are more frequently overweight [30] . Although no correlation between circulating TRAIL and BMI was found in patients with CVD [31] , a positive correlation between soluble TRAIL, serum LDLcholesterol and total body fat in elderly men and women has been reported [32] . We found that Trail , Trail −/− mice had increased adiposity, suggesting (e) Abcg5 mRNA levels were detected from the liver. f Srebp1, (g) Glut2 and (h) Ldlr mRNA were measured from liver. All mRNA levels were normalised to β-actin; n=6-8 per genotype. Results are expressed as mean±SEM; *p<0.05, **p<0.01 ***p<0.001and ****p <0.0001, as assessed by ANOVA that food intake may not fully explain the above observation. This is currently under investigation in our laboratory.
Trail −/− mice fed a 'Western' high-fat diet showed pancreatic inflammation, beta cell death and reduced insulin expression and secretion associated with hyperglycaemia and impaired glucose tolerance. In keeping with this, overabundance of TRAIL in pancreatic islets prolonged normoglycaemia and reduced severity of insulitis in a rat model of diabetes [33] ; TRAIL injection also improved islet damage in a mouse model of diabetes [34] . Apoe −/− mice had significantly higher macrophage numbers and caspase-3-positive cells than parental strains (Fig. 2g-h ). Macrophageassociated inflammation may therefore underlie the reduced islet function seen in Trail IL-6 is more likely to affect the pancreas. Interestingly, IL-6 secreted by inflammatory cells can induce beta cell death resulting in reduced insulin production [35] . In contrast, levels of plasma MCP-1 were more elevated in Trail
Apoe −/− and may contribute to the increased numbers of macrophages seen in pancreases and in atherosclerotic plaques ( Fig. 2g and 5c, Table 2 ). In both cases, macrophage-dense areas were approximately double those seen in Apoe −/− mice ( Fig. 2g and 5c, Table 2 ). TRAIL may be involved in monocyte recruitment to sites of chronic inflammation, as seen in type 1 diabetes [36] and in atherosclerosis [37] . Lack of TRAIL in Apoe −/− mice caused altered lipid metabolism, with significantly increased plasma cholesterol and triacylglycerol. There are three mechanisms to account for mice may be due to: (1) increased consumption of food (Fig. 1b) ; (2) significantly higher expression of Hmgcoar and Npc1l1 (Npc1l1-knockout mice cannot absorb dietary cholesterol and are protected from hyperlipidaemia and fatty liver [38, 39] ); and (3) the overproduction of triacylglycerol via activation of lipogenesis. GLUT2, the principle glucose transporter between liver and blood, allows passive glucose movement across cell membranes. In diabetic patients, liver GLUT2 abundance is increased [40] and controlled by glucose levels [41] . Glucose-stimulated Glut2 expression in the liver is mediated by sterol regulatory element binding protein-1 (SREBP1) [42] , which also mediates sterol biosynthesis by controlling transcriptional regulation of Ldlr [43] , which was also elevated in Trail animals [45] , although insulin levels were not checked and tolerance testing was not performed. Moreover, contents of 'Western' diets vary and the composition of that used by Watt et al. was not specified. We believe the differences in lesion development and plasma chemistry seen in these studies may result from differences in the fat content of the diets. It is clear from these studies that hyperglycaemia alone is insufficient to accelerate atherosclerosis in this model, since no lesions were apparent in Trail −/− mice. However, in our system, hyperglycaemia in concert with hyperlipidaemia leads to accelerated atherosclerosis. This is not surprising, as glucose and lipids act by the same mechanisms to initiate atherosclerotic lesions [46] . Increased infiltrating macrophages in Trail −/− Apoe −/− mice may stimulate movement of monocytes/macrophages or systemic inflammatory chemokines (such as MCP-1) to lesions and contribute to the severity of atherosclerosis. S100A9 is a biomarker for CVD. Interestingly, in a mouse model of diabetes, increased accumulation of S100A9-positive monocytic cells was observed in lesions [47] , supporting the notion that an inflammatory state contributes to atherosclerotic lesions in diabetes. In our model, diabetes was not artificially induced and atherosclerosis in Apoe −/− mice was exacerbated by the lack of TRAIL. We confirm a significant link between TRAIL, diabetes and atherosclerosis, and prove a causative rather than a consequential role for TRAIL in these pathological complications. More detailed comparisons of Trail −/− Apoe −/− and the parental mouse strains should further our understanding of TRAIL-dependent cellular/ molecular mechanisms of diabetes and its complications.
